Abstract
Raynaud’s phenomenon is a common feature among many autoimmune conditions and is often used to support the diagnosis of a rheumatic disease. Temperature sensitivity and digital discoloration, two key features of Raynaud’s, are shared by several other conditions which may complicate a clinical evaluation. An accurate diagnosis of Raynaud’s is critical in risk stratifying patients with early rheumatic disease and determining appropriate management. Physicians and other health care providers must be aware of these “mimics” and clearly distinguish them from Raynaud’s. This chapter begins with a detailed review of each of these conditions which include frostbite, primary pernio/chilblains, chilblain lupus, acrocyanosis, livedo reticularis and racemosa, and erythromelalgia.
Subsequently, the chapter will address other mimics of Raynaud’s that are also associated with digital color changes, but are distinguished from Raynaud’s by an absence of temperature sensitivity. Thoracic outlet syndrome and complex regional pain syndrome are both discussed in detail and important features of diagnosis and management are revealed. Thoracic outlet syndrome is important to accurately diagnose as it can be reversed with surgical intervention. Out of the three subtypes, arterial TOS is most important to quickly refer to a surgeon. Complex regional pain syndrome can have similar features to Raynaud’s, but the quality of the pain is the most distinguishing symptom.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- CRPS:
-
Complex regional pain syndrome
- FRRS:
-
First rib resection and anterior scalenectomy
- IASP:
-
International Association for the Study of Pain
- QSART:
-
Quantitative sudomotor axon reflex tear
- RSO:
-
Resting sweat output
- RST:
-
Resting skin temperature
- TOS:
-
Thoracic outlet syndrome
- TRVP:
-
Transient receptor vanilloid channels
References
Harirchi I, Arvin A, Vash JH, Zafarmand V. Frostbite: incidence and predisposing factors in mountaineers. Br J Sports Med. 2005;39(12):898–901. discussion 901.
Long 3rd WB, Edlich RF, Winters KL, Britt LD. Cold injuries. J Long Term Eff Med Implants. 2005;15(1):67–78.
Woo EK, Lee JW, Hur GY, Koh JH, Seo DK, Choi JK, et al. Proposed treatment protocol for frostbite: a retrospective analysis of 17 cases based on a 3-year single-institution experience. Arch Plast Surg. 2013;40(5):510–6.
Imray CH, Oakley EH. Cold still kills: cold-related illnesses in military practice freezing and non-freezing cold injury. J R Army Med Corps. 2005;151(4):218–22.
Valnicek SM, Chasmar LR, Clapson JB. Frostbite in the prairies: a 12-year review. Plast Reconstr Surg. 1993;92(4):633–41.
Imray CH, Richards P, Greeves J, Castellani JW. Nonfreezing cold-induced injuries. J R Army Med Corps. 2011;157(1):79–84.
Hallam MJ, Cubison T, Dheansa B, Imray C. Managing frostbite. BMJ. 2010;341:c5864.
Johnson-Arbor K. Images in clinical medicine. Digital frostbite. N Engl J Med. 2014;370(2):e3.
Khan MI, Tariq M, Rehman A, Zafar A, Sheen SN. Efficacy of cervicothoracic sympathectomy versus conservative management in patients suffering from incapacitating Raynaud’s syndrome after frost bite. J Ayub Med Coll Abbottabad. 2008;20(2):21–4.
Bouwman DL, Morrison S, Lucas CE, Ledgerwood AM. Early sympathetic blockade for frostbite – is it of value? J Trauma. 1980;20(9):744–9.
Cauchy E, Cheguillaume B, Chetaille E. A controlled trial of a prostacyclin and rt-PA in the treatment of severe frostbite. N Engl J Med. 2011;364(2):189–90.
Twomey JA, Peltier GL, Zera RT. An open-label study to evaluate the safety and efficacy of tissue plasminogen activator in treatment of severe frostbite. J Trauma. 2005;59(6):1350–4. discussion 1354–5.
Sheridan RL, Goldstein MA, Stoddard Jr FJ, Walker TG. Case records of the Massachusetts General Hospital. Case 41-2009. A 16-year-old boy with hypothermia and frostbite. N Engl J Med. 2009; 361(27):2654–62.
Finderle Z, Cankar K. Delayed treatment of frostbite injury with hyperbaric oxygen therapy: a case report. Aviat Space Environ Med. 2002;73(4):392–4.
von Heimburg D, Noah EM, Sieckmann UP, Pallua N. Hyperbaric oxygen treatment in deep frostbite of both hands in a boy. Burns. 2001;27(4):404–8.
Miller MB, Koltai PJ. Treatment of experimental frostbite with pentoxifylline and aloe vera cream. Arch Otolaryngol Head Neck Surg. 1995;121(6):678–80.
Hayes Jr DW, Mandracchia VJ, Considine C, Webb GE. Pentoxifylline. Adjunctive therapy in the treatment of pedal frostbite. Clin Podiatr Med Surg. 2000;17(4):715–22.
Johnson AR, Jensen HL, Peltier G, DelaCruz E. Efficacy of intravenous tissue plasminogen activator in frostbite patients and presentation of a treatment protocol for frostbite patients. Foot Ankle Spec. 2011;4(6):344–8.
Taylor MS. Lumbar epidural sympathectomy for frostbite injuries of the feet. Mil Med. 1999; 164(8):566–7.
Chandran GJ, Chung B, Lalonde J, Lalonde DH. The hyperthermic effect of a distal volar forearm nerve block: a possible treatment of acute digital frostbite injuries? Plast Reconstr Surg. 2010;126(3):946–50.
Jacob JR, Weisman MH, Rosenblatt SI, Bookstein JJ. Chronic pernio. A historical perspective of cold-induced vascular disease. Arch Intern Med. 1986; 146(8):1589–92.
Prakash S, Weisman MH. Idiopathic chilblains. Am J Med. 2009;122(12):1152–5.
Goette DK. Chilblains (perniosis). J Am Acad Dermatol. 1990;23(2 Pt 1):257–62.
Larkins N, Murray KJ. Major cluster of chilblain cases in a cold dry Western Australian winter. J Paediatr Child Health. 2013;49(2):144–7.
Page EH, Shear NH. Temperature-dependent skin disorders. J Am Acad Dermatol. 1988;18(5 Pt 1):1003–19.
Takci Z, Vahaboglu G, Eksioglu H. Epidemiological patterns of perniosis, and its association with systemic disorder. Clin Exp Dermatol. 2012;37(8):844–9.
Simon TD, Soep JB, Hollister JR. Pernio in pediatrics. Pediatrics. 2005;116(3):e472–5.
Padeh S, Gerstein M, Greenberger S, Berkun Y. Chronic chilblains: the clinical presentation and disease course in a large paediatric series. Clin Exp Rheumatol. 2013;31(3):463–8.
Klippel JH. Raynaud’s phenomenon. The French tricolor. Arch Intern Med. 1991;151(12):2389–93.
Arias-Santiago SA, Giron-Prieto MS, Callejas-Rubio JL, Fernandez-Pugnaire MA, Ortego-Centeno N. Lupus pernio or chilblain lupus?: two different entities. Chest. 2009;136(3):946–7. author reply 947.
Vano-Galvan S, Martorell A. Chilblains. CMAJ. 2012;184(1):67.
Cribier B, Djeridi N, Peltre B, Grosshans E. A histologic and immunohistochemical study of chilblains. J Am Acad Dermatol. 2001;45(6):924–9.
Dowd PM, Rustin MH, Lanigan S. Nifedipine in the treatment of chilblains. Br Med J (Clin Res Ed). 1986;293(6552):923–4.
Rustin MH, Newton JA, Smith NP, Dowd PM. The treatment of chilblains with nifedipine: the results of a pilot study, a double-blind placebo-controlled randomized study and a long-term open trial. Br J Dermatol. 1989;120(2):267–75.
Spittell Jr JA, Spittell PC. Chronic pernio: another cause of blue toes. Int Angiol. 1992;11(1):46–50.
Viguier M, Pinquier L, Cavelier-Balloy B, de la Salmoniere P, Cordoliani F, Flageul B, et al. Clinical and histopathologic features and immunologic variables in patients with severe chilblains. A study of the relationship to lupus erythematosus. Medicine (Baltimore). 2001;80(3):180–8.
Souwer IH, Lagro-Janssen AL. Chronic chilblains. BMJ. 2011;342:d2708.
Hedrich CM, Fiebig B, Hauck FH, Sallmann S, Hahn G, Pfeiffer C, et al. Chilblain lupus erythematosus – a review of literature. Clin Rheumatol. 2008;27(10):1341.
Rice G, Newman WG, Dean J, Patrick T, Parmar R, Flintoff K, et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet. 2007;80(4):811–5.
Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007;39(9):1065–7.
Lee-Kirsch MA, Chowdhury D, Harvey S, Gong M, Senenko L, Engel K, et al. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med (Berl). 2007;85(5):531–7.
Tungler V, Silver RM, Walkenhorst H, Gunther C, Lee-Kirsch MA. Inherited or de novo mutation affecting aspartate 18 of TREX1 results in either familial chilblain lupus or Aicardi-Goutieres syndrome. Br J Dermatol. 2012;167(1):212–4.
Su WP, Perniciaro C, Rogers 3rd RS, White Jr JW. Chilblain lupus erythematosus (lupus pernio): clinical review of the Mayo Clinic experience and proposal of diagnostic criteria. Cutis. 1994;54(6): 395–9.
Boehm I, Bieber T. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol. 2001;137(2):235–6.
Millard LG, Rowell NR. Chilblain lupus erythematosus (Hutchinson). A clinical and laboratory study of 17 patients. Br J Dermatol. 1978;98(5):497–506.
Kurklinsky AK, Miller VM, Rooke TW. Acrocyanosis: the Flying Dutchman. Vasc Med. 2011;16(4):288–301.
Neri P, Messerotti A, Lonardo A, Capatti C, Melini L. Acrocyanosis as a heralding sign of ovarian benign teratoma. Am J Hematol. 1996;53(1):53.
Legrain S, Raguin G, Piette JC. Digital necrosis revealing ovarian cancer. Dermatology. 1999;199(2):183–4.
Poszepczynska-Guigne E, Viguier M, Chosidow O, Orcel B, Emmerich J, Dubertret L. Paraneoplastic acral vascular syndrome: epidemiologic features, clinical manifestations, and disease sequelae. J Am Acad Dermatol. 2002;47(1):47–52.
Chow SF, McKenna CH. Ovarian cancer and gangrene of the digits: case report and review of the literature. Mayo Clin Proc. 1996;71(3):253–8.
Anderson RP, Morris BA. Acrocyanosis due to imipramine. Arch Dis Child. 1988;63(2):204–5.
Karakaya I, Aydogan M, Coskun A, Gokalp AS. Acrocyanosis as a side effect of tricyclic antidepressants: a case report. Turk J Pediatr. 2003;45(2):155–7.
Campo-Voegeli A, Estrach T, Marti RM, Corominas N, Tuset M, Mascaro JM. Acrocyanosis induced by interferon alpha(2a). Dermatology. 1998;196(3):361–3.
Dickerman JD, Howard P, Dopp S, Staley R. Infectious mononucleosis initially seen as cold-induced acrocyanosis: association with auto-anti-M and anti-I antibodies. Am J Dis Child. 1980;134(2):159–60.
Heidrich H. Functional vascular diseases: Raynaud’s syndrome, acrocyanosis and erythromelalgia. Vasa. 2010;39(1):33–41.
Parsi K, Partsch H, Rabe E, Ramelet AA. Reticulate eruptions: part 2. Historical perspectives, morphology, terminology and classification. Australas J Dermatol. 2011;52(4):237–44.
Thornsberry LA, LoSicco KI, English 3rd JC. The skin and hypercoagulable states. J Am Acad Dermatol. 2013;69(3):450–62.
Kraemer M, Linden D, Berlit P. The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review. J Neurol. 2005;252(10):1155–66.
Gibbs MB, English 3rd JC, Zirwas MJ. Livedo reticularis: an update. J Am Acad Dermatol. 2005; 52(6):1009–19.
Parsi K, Partsch H, Rabe E, Ramelet AA. Reticulate eruptions. Part 1: vascular networks and physiology. Australas J Dermatol. 2011;52(3):159–66.
Asherson RA, Cervera R, Shepshelovich D, Shoenfeld Y. Nonthrombotic manifestations of the antiphospholipid syndrome: away from thrombosis? J Rheumatol. 2006;33(6):1038–44.
Asherson RA, Frances C, Iaccarino L, Khamashta MA, Malacarne F, Piette JC, et al. The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy. Clin Exp Rheumatol. 2006;24((1 Suppl 40)):S46–51.
Frances C, Niang S, Laffitte E, Pelletier F, Costedoat N, Piette JC. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum. 2005;52(6):1785–93.
Uthman IW, Khamashta MA. Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rheumatol. 2006;33(12):2379–82.
Hughes GR. Autoantibodies in lupus and its variants: experience in 1000 patients. Br Med J (Clin Res Ed). 1984;289(6441):339–42.
Weinstein C, Miller MH, Axtens R, Buchanan R, Littlejohn GO. Livedo reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erythematosus. Arch Dermatol. 1987;123(5):596–600.
Weinstein S, Piette W. Cutaneous manifestations of antiphospholipid antibody syndrome. Hematol Oncol Clin North Am. 2008;22(1):67–77. vi.
Waxman SG, Dib-Hajj SD. Erythromelalgia: a hereditary pain syndrome enters the molecular era. Ann Neurol. 2005;57(6):785–8.
Skeik N, Rooke TW, Davis MD, Davis DM, Kalsi H, Kurth I, et al. Severe case and literature review of primary erythromelalgia: novel SCN9A gene mutation. Vasc Med. 2012;17(1):44–9.
Egri C, Ruben PC. A hot topic: temperature sensitive sodium channelopathies. Channels (Austin). 2012;6(2):75–85.
Davis MD, O’Fallon WM, Rogers 3rd RS, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol. 2000;136(3):330–6.
van Genderen PJ, Michiels JJ, Drenth JP. Hereditary erythermalgia and acquired erythromelalgia. Am J Med Genet. 1993;45(4):530–2.
Reed KB, Davis MD. Incidence of erythromelalgia: a population-based study in Olmsted County Minnesota. J Eur Acad Dermatol Venereol. 2009;23(1):13–5.
Drenth JP, Michiels JJ. Erythromelalgia and erythermalgia: diagnostic differentiation. Int J Dermatol. 1994;33(6):393–7.
Cook-Norris RH, Tollefson MM, Cruz-Inigo AE, Sandroni P, Davis MD, Davis DM. Pediatric erythromelalgia: a retrospective review of 32 cases evaluated at Mayo Clinic over a 37-year period. J Am Acad Dermatol. 2012;66(3):416–23.
Mork C, Asker CL, Salerud EG, Kvernebo K. Microvascular arteriovenous shunting is a probable pathogenetic mechanism in erythromelalgia. J Invest Dermatol. 2000;114(4):643–6.
Berlin AL, Pehr K. Coexistence of erythromelalgia and Raynaud’s phenomenon. J Am Acad Dermatol. 2004;50(3):456–60.
Paira S, Cassano G, Korol V, Ortiz A, Roverano S. Erythromelalgia with subsequent digital necrosis, glomerulonephritis, and antiphospholipid antibodies. J Clin Rheumatol. 2005;11(4):209–12.
Thompson GH, Hahn G, Rang M. Erythromelalgia. Clin Orthop Relat Res. 1979;144:249–54.
van Genderen PJ, Michiels JJ. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost. 1997;23(4):357–63.
Michiels JJ, Drenth JP. Erythromelalgia and erythermalgia: lumpers and splitters. Int J Dermatol. 1994;33(6):412–3.
Kurzrock R, Cohen PR. Erythromelalgia and myeloproliferative disorders. Arch Intern Med. 1989; 149(1):105–9.
Kurzrock R, Cohen PR. Paraneoplastic erythromelalgia. Clin Dermatol. 1993;11(1):73–82.
Michiels JJ, van Joost T. Erythromelalgia and thrombocythemia: a causal relation. J Am Acad Dermatol. 1990;22(1):107–11.
Davis MD, Rooke TW, Sandroni P. Mechanisms other than shunting are likely contributing to the pathophysiology of erythromelalgia. J Invest Dermatol. 2000;115(6):1166–7.
Genebriera J, Michaels JD, Sandroni P, Davis MD. Results of computer-assisted sensory evaluation in 41 patients with erythromelalgia. Clin Exp Dermatol. 2012;37(4):350–4.
Davis MD, Rooke T. Erythromelalgia. Curr Treat Options Cardiovasc Med. 2006;8(2):153–65.
Peet RM, Henriksen JD, Anderson TP, Martin GM. Thoracic outlet syndrome: evaluation of a therapeutic exercise program. Proc Staff Meet Mayo Clin. 1956;31:281–7.
Stopford JS, Telford ED. Compression of the lower trunk of the brachial plexus by a first dorsal rib: with a note on the surgical treatment. Br J Surg. 1919;7:168–77.
Eden KC. Complications of cervical rib: vascular complications of cervical ribs and first thoracic rib abnormalities. Br J Surg. 1939/1940;27:111–39.
Cormier JM, Amrane M, Ward A, Laurian C, Gigou F. Arterial complications of thoracic outlet syndrome. J Vasc Surg. 1989;9:778–87.
Hood DB, Kuehne J, Yellin AE, Weaver FA. Vascular complications of thoracic outlet syndrome. Am Surg. 1997;63:913–7.
Sanders RJ, Hammond SL, Rao NM. Thoracic outlet syndrome: a review. Neurologist. 2008;14:365–73.
Kai Y, Oyama M, Kurose S, Inadome T, Oketani Y, Masuda Y. Neurogenic thoracic outlet syndrome in whiplash injury. J Spinal Disord. 2001;14:487–93.
Sanders RJ, Haug CE. Thoracic outlet syndrome: a common sequela of neck injuries. In: Thoracic outlet syndrome. Philadelphia: Lippinoctt; 1991:26.
Sanders RJ, Hammond SL, Rao NM. Diagnosis of thoracic outlet syndrome. J Vasc Surg. 2007;46:601–4.
Stapleton C, Herrington L, George K. Sonographic evaluation of the subclavian artery during thoracic outlet syndrome shoulder maneuvers. Man Ther. 2009;14:19–27.
Brantigan CO, Roos DB. Diagnosing thoracic outlet syndrome. Hand Clin. 2004;20:27–36.
Filler AG, Maravilla KR, Tsuruda JS. MR neurography and muscle MR imaging for image diagnosis of disorders affecting the peripheral nerves and musculature. Neurol Clin. 2004;22:643–82.
Brooke BS, Freischlag JA. Contemporary management of thoracic outlet syndrome. Curr Opin Cardiol. 2010;25:535–40.
Jordan SE, Machieder HI. Diagnosis of thoracic outlet syndrome using electrophysiologically guided anterior scalene blocks. Ann Vasc Surg. 1998;12:260–4.
Torriani M, Gupta R, Donahue DM. Sonographically guided anesthetic injection of anterior scalene muscles for treatment of neurogenic thoracic outlet syndrome. Ann Vasc Surg. 2000;14:365–9.
Criado E, Berguer R, Greenfield L. The spectrum of arterial compression at the thoracic outlet. J Vasc Surg. 2010;52:406–11.
Jordan SE, Ahn SS, Freischlag JA, Gelabert HA, Machleder HI. Selective botulinum chemodenervation of the scalene muscles for treatment of neurogenic thoracic outlet syndrome. Ann Vasc Surg. 2000;14:365–9.
Christo PJ, Christo DK, Carinci AJ, Freischlag JA. Single CT-guided chemodenervation of the anterior scalene muscle with botulism toxin for neurogenic thoracic outlet syndrome. Pain Med. 2010;11:504–11.
Torriani M, Gupta R, Donahue DM. Botulinum toxin injection in neurogenic thoracic outlet syndrome: results and experience using an ultrasound-guided approach. Skeletal Radiol. 2010;39:973–80.
Lee JT, Karwowski JK, Harris EJ, Haukoos JS, Olcott 4th C. Long-term thrombotic recurrence after nonoperative management of Paget-Schroetter syndrome. J Vasc Surg. 2006;43:1236–43.
Molina JE, Hunter DW, Dietz CA. Paget-Schroetter syndrome treated with thrombolytics and immediate surgery. J Vasc Surg. 2007;45:328–34.
de Leon RA, Chang DC, Hassoun HT, Black JH, Roseborough GS, Perler BA, et al. Multiple treatment algorithms for successful outcomes in venous thoracic outlet syndrome. Surgery. 2009;145:500–7.
Caparrelli DJ, Freischlag J. A unified approach to axillosubclavian venous thrombosis in a single hospital admission. Semin Vasc Surg. 2005;18:153–7.
Urschel HC, Raazzuk MA. Paget-Schroetter syndrome: what is the best management? Ann Thorac Surg. 2000;69:1663–9.
Merskey H, Bogduk N. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. 2nd ed. Seattle, WA: IASP Press; 1994.
Bruehl S, Harden RN, Galer BS, Saltz S, Backonja M, Stanton-Hicks M. Complex regional pain syndrome: are there distinct subtypes and sequential stages of the syndrome? Pain. 2002;95:119–24.
Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy, prospective study of 829 patients. Lancet. 1993;342:1012–6.
de Boer RD, Marinus J, van Hilten JJ, Huygen FJ, van Eijs F, van Kleef M, et al. Distribution of signs and symptoms of complex regional pain syndrome type I in patients meeting the diagnostic criteria of the International Association for the Study of Pain. Eur J Pain. 2011;15:831–8.
Van Laere M, Claessens M. The treatment of reflex sympathetic dystrophy syndrome: current concepts. Acta Orthop Belg. 1992;58 Suppl 1:259–61.
Cohen H, McCabe C, Harris N, Hall J, Lewis J, Blake DR. Clinical evidence of parietal cortex dysfunction and correlation with extent of allodynia in CRPS type I. Eur J Pain. 2013;17:527–38.
Acerra NE, Moseley GL. Dysynchiria: watching the mirror image of the unaffected limb elicits pain on the affected side. Neurology. 2005;65:751–3.
Harden NR, Bruehl S, Perez R. Validation of proposed diagnostic criteria (the “Budapest Criteria”) for complex regional pain syndrome. Pain. 2010;150(2):268–74.
Chleimsky TC, Low PA, Naessens JM, Wilson PR, Amadio PC, O’Brien PC. Value of autonomic testing in reflex sympathetic dystrophy. Mayo Clin Proc. 1995;70:1029–40.
Lee GW, Weeks PM. The role of bone scintigraphy in diagnosing reflex sympathetic dystrophy. J Hand Surg Am. 1995;20:458–63.
Cappello ZJ, Kasdan ML, Louis DS. Meta-analysis of imaging techniques for the diagnosis of complex regional pain syndrome type I. J Hand Surg Am. 2012;37:288–96.
Varenna M, Adami S, Rossini M, Gatti D, Idolazzi L, Zucchi F, et al. Treatment of complex regional pain syndrome type I with neridronate: a randomized, double blind placebo-controlled study. Rheumatology (Oxford). 2013;52:534–42.
O’Connell NE, Wand BM, McAuley J, Marston L, Moseley GL. Interventions for treating pain and disability in adults with complex regional pain syndrome – an overview of systematic reviews. Cochrance Database Syst Rev. 2013;4, CD009416.
Borchers AT, Gershwin ME. Complex regional pain syndrome: a comprehensive and critical review. Autoimmun Rev. 2013;13(3):242–65. http://dx.doi.org; 10.1016/j.autrev.2013.10.0006.
Acknowledgement
We acknowledge Dr. Stefan Zimmeran for his image of arterial thoracic outlet syndrome as shown in (Fig. 11.9).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
McMahan, Z.H., Paik, J.J. (2015). Raynaud’s Mimics. In: Wigley, F., Herrick, A., Flavahan, N. (eds) Raynaud’s Phenomenon. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1526-2_11
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1526-2_11
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1525-5
Online ISBN: 978-1-4939-1526-2
eBook Packages: MedicineMedicine (R0)